• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Cytotoxic Payloads for Antibody-Drug Conjugates

Cytotoxic Payloads for Antibody-Drug Conjugates

Hardcover

Series: Drug Discovery, Book 71

Medical ReferenceChemistry

ISBN10: 1788010779
ISBN13: 9781788010771
Publisher: Royal Society of Chemistry
Published: Jul 15 2019
Pages: 480
Weight: 2.05
Height: 1.26 Width: 6.22 Depth: 9.53
Language: English

Antibody-drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla(TM)), brentuximab vedotin (Adcetris(TM)), inotuzumab ozogamicin (Besponsa(TM)), gemtuzumab ozogamicin (Mylotarg(TM)) and moxetumomab pasudotox-tdfk (Lumoxiti(R))] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many.

Also in

Medical Reference